Hong Kong strife holds up al­most $100M of BioN­Tech's Se­ries B haul

Late on Mon­day, it was re­vealed that Ger­man can­cer drug de­vel­op­er BioN­Tech is eye­ing a $100 mil­lion pub­lic list­ing in the Unit­ed States, two months af­ter the can­cer-fo­cused com­pa­ny un­veiled a her­culean $325 mil­lion in an up­sized round of fi­nanc­ing.

In the IPO fil­ing, how­ev­er, the Mainz-based drug de­vel­op­er re­vealed that shares worth about $97 mil­lion that were ex­pect­ed to be bought by an undis­closed Hong Kong-based in­vestor have been de­layed, in part due to the po­lit­i­cal un­rest in Hong Kong and the on­go­ing trade dis­pute be­tween the Unit­ed States and Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER